NCT06429800View on ClinicalTrials.gov

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 16, 2025

Primary Completion Date

April 16, 2025

Study Completion Date

April 16, 2025

Conditions
Lupus NephritisSystemic Lupus Erythematosus
Interventions
DRUG

ATA3219

ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.

Trial Locations (1)

91320

Atara Biotherapeutics, Thousand Oaks

Sponsors
All Listed Sponsors
lead

Atara Biotherapeutics

INDUSTRY

NCT06429800 - A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter